Source-grounded facts extracted from Progyny, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Progyny, Inc. shareholders approved Approval of the Amendment to the Company’s Certificate of Incorporation to Eliminate the Default Supermajority Voting Requirement Concerning Certain Business Combinations.
“Stockholders approved the amendments to eliminate the default supermajority voting requirement concerning certain business combinations.”
Progyny, Inc. shareholders approved Approval of the Amendment to the Company’s Certificate of Incorporation to Eliminate Certain Supermajority Voting Requirements.
“Stockholders approved the Supermajority Amendments.”
Progyny, Inc. shareholders approved Approval, on an Advisory (Non-Binding) Basis, of the Compensation of the Company’s Named Executive Officers.
“Stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers.”
Progyny, Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm at the 2026-12-31 meeting.
“Stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Progyny, Inc. shareholders approved Election of Class I Directors.
“Each of the Class I director nominees of the Board was elected to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successor has been duly elected, or if sooner, until their resignation, death, or removal from the Board of Directors.”
Progyny, Inc.: Board approved amendments to the bylaws consistent with the supermajority amendments, eliminating supermajority vote requirement to remove directors with cause and to amend the bylaws (effective 2026-05-21).
“In connection with the Charter Amendments, the Company’s Board of Directors (the “Board”) approved certain amendments to the Company’s Second Amended and Restated Bylaws (as so amended and restated, the “Third Amended and Restated Bylaws”) consistent with the Supermajority Amendments. The Third Amended and Restated Bylaws amend Article IV, Section 21 and Article XIII, Section 47 to eliminate the supermajority vote requirement to remove directors with cause and to amend the bylaws, respectively. The Third Amended and Restated Bylaws became effective on May 21, 2026.”
Progyny, Inc.: Stockholders approved amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements and eliminate the default supermajority voting requirement concerning certain business combinations (effective 2026-05-21).
“Progyny, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the Company’s stockholders approved certain amendments (the “Charter Amendments”) to the Company’s Certificate of Incorporation. As further described in Proposals 4 and 5 of the Company’s definitive proxy statement filed on April 10, 2026 (the “Proxy Statement”), the Charter Amendments (a) eliminate certain supermajority voting requirements (the “Supermajority Amendments”), and (b) eliminate the default supermajority voting requirement concerning certain business combinations. The Charter Amendments became effective upon the filing of a Certificate of Amendment (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on May 21, 2026.”
Progyny, Inc. reported the three-month period ended March 31, 2026 results: revenue $328,504, net income $24,232, EPS $0.29.
“returned value to our investors by repurchasing 8.8 million shares.” First Quarter 2026 Highlights: (unaudited; in thousands, except per share amounts) 1Q 2026 1Q 2025 Revenue $328,504 $324,038 Gross Profit $83,071 $75,795 Gross Margin 25.3% 23.4% Net Income $24,232 $15,059 Net Income per Diluted Share 1 $0.29 $0.17 Adjusted Earnings per Diluted Share 2 $0.50”
Progyny, Inc. incurred revolving credit of $200.0 million with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swingline lender at adjusted SOFR, or the alternate base rate, plus, in each case, an applicable mar maturing July 1, 2030.
“but not defined herein shall have the meanings assigned to such terms in the Credit Agreement. The Credit Agreement makes available to the Company a maximum aggregate amount of $200.0 million of revolving loan commitments, which may be drawn, subject to customary borrowing conditions, until maturity on July 1, 2030. Subject to certain conditions, the Company may at”
Dr. Fred E. Cohen departed as Director at Progyny, Inc..
“On April 9, 2025, Dr. Fred E. Cohen notified the Board of Directors of Progyny, Inc. (the “Company”) of his decision not to stand for reelection at the Company’s 2025 Annual Meeting of Stockholders.”
Debra Morris was appointed as Class III Director at Progyny, Inc..
“On January 10, 2025, the board of directors (the “Board”) of Progyny, Inc. (the “Company”) appointed Debra Morris to serve as a Class III director of the Company, effective January 16, 2025.”
Progyny, Inc. reported the three-month period ended March 31, 2024 results: revenue $278,078, net income $16,898, EPS $0.17.
“of February,” said Mark Livingston, Progyny’s Chief Financial Officer. First Quarter 2024 Highlights: (unaudited; in thousands, except per share amounts) 1Q 2024 1Q 2023 Revenue $278,078 $258,394 Gross Profit $62,406 $58,640 Gross Margin 22.4% 22.7% Net Income $16,898 $17,678 Net Income per Diluted Share 1 $0.17 $0.18 Adjusted Earnings Per Diluted Share 2 $0.39”
Progyny, Inc. reported the three- and twelve-month periods ended December 31, 2023 results: revenue $1,088.6 Million, net income $62,037, EPS $0.62. Guidance initiated.
“Progyny, Inc. Announces Fourth Quarter 2023 Results Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% Growth Achieves 49% Growth in Adjusted EBITDA to Record $187.1 Million Issues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint”
Progyny, Inc. reported financial results for the fiscal quarter and year ended December 31, 2023.
“On February 27, 2024, Progyny, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.”
Progyny, Inc. reported three-month period ended September 30, 2023 results: revenue $280,891, net income $15,898, EPS $0.16. Guidance raised.
“said Mark Livingston, Progyny’s Chief Financial Officer. Third Quarter 2023 Highlights: (unaudited; in thousands, except per share amounts) 3Q 2023 3Q 2022 Revenue $280,891 $205,371 Gross Profit $62,624 $45,995 Gross Margin 22.3% 22.4% Net Income $15,898 $13,211 Net Income per Diluted Share 1 $0.16 $0.13 Adjusted EBITDA 2 $50,019 $34,957 Adjusted”
Progyny, Inc. reported three-month period ended June 30, 2023 results: revenue $279,373, net income $14,991, EPS $0.15. Guidance raised.
“quarter,” said Mark Livingston, Progyny’s Chief Financial Officer. Second Quarter 2023 Highlights: (unaudited; in thousands, except per share amounts) 2Q 2023 2Q 2022 Revenue $279,373 $195,004 Gross Profit $60,641 $43,887 Gross Margin 21.7% 22.5% Net Income $14,991 $8,768 Net Income per Diluted Share 1 $0.15 $0.09 Adjusted EBITDA 2 $47,464 $32,878 Adjusted”
Progyny, Inc. shareholders rejected Approval, on a Non-Binding Advisory Basis, of the Compensation of our Named Executive Officers at the 2023-05-24 meeting.
“Stockholders approved, on a non-binding advisory basis, the compensation paid to Progyny’s named executive officers for the fiscal year ending December 31, 2023.”
Progyny, Inc. shareholders approved Ratification of Ernst & Young LLP as our Independent Registered Public Accounting Firm at the 2023-05-24 meeting.
“Stockholders ratified the appointment of Ernst & Young LLP as Progyny’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Progyny, Inc. shareholders approved Election of Class I directors at the 2023-05-24 meeting.
“Each of the Class I director nominees to the Board of Directors was elected to serve until Progyny’s 2026 Annual Meeting of Stockholders and until his or her successor has been duly elected, or if sooner, until he or she resigns, dies, or is removed from the Board of Directors.”
Progyny, Inc. reported first quarter of 2023 results: revenue $258.4 million, net income $17.7 million, EPS $0.18. Guidance raised.
“Revenue was $258.4 million, a 50% increase as compared to the $172.2 million reported in the first quarter of 2022, primarily as a result of the increase in our number of clients and covered lives. • Fertility benefit services revenue was $157.1 million, a 42% increase from the $110.9 million reported in the first quarter of 2022. • Pharmacy benefit services revenue was $101.2 million, a 65% increase as compared to the $61.3 million reported in the first quarter of 2022. Gross profit was $58.6 million, an increase of 78% from the $32.9 million reported in the first quarter of 2022, primarily due to the higher revenue. Gross margin was 22.7%, an increase of 360 basis points from the 19.1% reported in the prior year period, primarily due to ongoing efficiencies realized in the delivery of our care management services . Net income was $17.7 million, or $0.18 income per diluted share, an increase of 256% as compared to the $5.0 million, or $0.05 income per diluted share, reported in the fi”
Progyny, Inc. reported the fiscal year ended December 31, 2022 results: revenue $786.9 million, net income $30.4 million, EPS $0.30 per diluted share.
“regardless of any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- Progyny, Inc. Announces Fourth Quarter 2022 Results Reports Full Year Revenue of $786.9 Million, Reflecting 57% Growth Reports Record Quarterly Revenue and Operating Cash Flow of $214.3 Million and $51.5 Million, Respectively Issues Financial Guidance for 2023, Anticipates”
Progyny, Inc. reported the fourth quarter of 2022 results: revenue $214.3 million, net income $3.4 million, EPS $0.03 per diluted share.
“Inc. Announces Fourth Quarter 2022 Results Reports Full Year Revenue of $786.9 Million, Reflecting 57% Growth Reports Record Quarterly Revenue and Operating Cash Flow of $214.3 Million and $51.5 Million, Respectively Issues Financial Guidance for 2023, Anticipates Crossing $1 Billion Revenue Milestone NEW YORK, February 27, 2023 /GlobeNewswire/ - Progyny, Inc.”
Progyny, Inc. updated its quarter and year ended December 31, 2022 guidance (reaffirmed).
“Progyny, Inc. (the “Company”) issued a press release to reaffirm the Company’s previously issued financial guidance for the three months and year ending December 31, 2022.”
Progyny, Inc. reported the three-month period ended September 30, 2022 results: revenue $205,371, net income $13,211, EPS $0.13. Guidance raised.
“said Mark Livingston, Progyny’s Chief Financial Officer. Third Quarter 2022 Highlights: (unaudited; in thousands, except per share amounts) 3Q 2022 3Q 2021 Revenue $205,371 $122,284 Gross Profit $45,995 $28,492 Gross Margin 22.4% 23.3% Net Income $13,211 $16,796 Net Income per Diluted Share 1 $0.13 $0.17 Adjusted EBITDA 2 $34,957 $16,479 Adjusted”
Lloyd H. Dean was appointed as Class I director at Progyny, Inc..
“On August 30, 2022, the board of directors (the " Board ") of Progyny, Inc. (the " Company ") increased the size of its Board from nine (9) to ten (10) directors and appointed Lloyd H. Dean to serve as Class I director of the Company, effective as of such date.”
Malissia Clinton resigned as Director at Progyny, Inc..
“On April 2, 2022, Malissia Clinton notified the board of directors (the “Board”) of Progyny, Inc. (the “Company”) of her resignation from the Board and from the Nominating and Corporate Governance Committee of the Board, in each case effective April 18, 2022.”
Michael Sturmer changed role as President at Progyny, Inc..
“Michael Sturmer, 45, who currently serves as Executive Vice President, Chief Growth and Strategy Officer, will succeed Mr. Anevski as President, effective as of January 1, 2022.”
Pete Anevski was appointed as Director at Progyny, Inc..
“the Board has appointed Mr. Anevski as a director of the Company effective as of the date he becomes Chief Executive Officer.”
Pete Anevski changed role as Chief Executive Officer at Progyny, Inc..
“Pete Anevski, 54, who currently serves as President and Chief Operating Officer, will succeed Mr. Schlanger as Chief Executive Officer, effective as of January 1, 2022.”
Beth Seidenberg was appointed as Lead Independent Director at Progyny, Inc..
“Beth Seidenberg, M.D., who currently serves as Chair of the Board, will assume the position of Lead Independent Director.”
David Schlanger changed role as Executive Chairman at Progyny, Inc..
“On November 4, 2021, Progyny, Inc. (the “Company”) announced that David Schlanger plans to transition to the role of Executive Chairman, effective as of January 1, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.